Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Annals of the New York Academy of Sciences|December 31, 2005
A role for Hath1, a bHLH transcription factor, in colon adenocarcinomaChing Ching Leow, Paul Polakis, Wei-Qiang GaoMabs|January 16, 2014
Site-specific antibody drug conjugates for cancer therapySiler Panowski, Sunil Bhakta, Helga Raab, et al.Molecular Cancer Therapeutics|March 22, 2014
MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanomaJyoti Asundi, Jennifer A Lacap, Suzanna Clark, et al.Cancer Research|September 3, 2004
Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cellsChing Ching Leow, Maria S Romero, Sarajane Ross, et al.Plos One|May 15, 2008
Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signalingBu-Er Wang, Xi-De Wang, James A Ernst, et al.Cancer Research|June 5, 2007
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivoVenita I DeAlmeida, Li Miao, James A Ernst, et al.Cancer Research|February 7, 2012
Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5Bob Y Liu, Irina Soloviev, XiaoDong Huang, et al.Nature Biotechnology|January 31, 2006
Identification and immunotherapeutic targeting of antigens induced by chemotherapyBonnee Rubinfeld, Archana Upadhyay, Suzanna L Clark, et al.Plos One|January 21, 2010
Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cellsBob Y Liu, Irina Soloviev, Peter Chang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2011
An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanomaJyoti Asundi, Chae Reed, Jennifer Arca, et al.Pageof 6